New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
March 5, 2019 - The FDA announced the approval of Janssen and J&J’s Spravato (esketamine), in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults.
Download PDF
Return to publications
